-

Importance of Rapid Lyme Disease Testing To Be Discussed in Free Webinar Hosted by Industry-Leading Quidel Corporation

SAN DIEGO--(BUSINESS WIRE)--As America is painfully learning through the current coronavirus pandemic, reliable testing with quick and accurate results is the key to stopping a disease in its tracks and providing time-sensitive treatment to the afflicted.

With Lyme season once again beginning and as many as 400,000 Americans likely to be impacted by this disease, Quidel Corporation is hosting a free educational webinar on May 13 to discuss options and clinical applications when testing for Lyme disease.

Quidel is a California-based diagnostic healthcare manufacturer and one of the nation’s leaders in developing rapid diagnostic health solutions. It is also the company behind the innovative Sofia 2 in-office Lyme test that provides a patient as well as his or her physician with indicative results within minutes as opposed to days, which has historically been the norm. Performed in the privacy of a doctor’s office or local clinic, it is also the only test that can get results from a simple finger prick of blood.

Lyme disease is a bacterial infection that is spread when people are bitten by an infected deer tick. Unlike a mosquito bite where people know immediately if they have been bitten, one of the challenges with Lyme disease is that symptoms usually will not appear for two to six weeks and may appear in a low-visibility area of the body such as in hair, an underarm or groin. At that point, typical symptoms include fever, headache, fatigue, joint pain, weakness in the limbs, and often a characteristic skin rash with a bull's-eye pattern. With appropriate antibiotic treatment, most people with Lyme disease recover completely; but the key is catching it early, and that means not hesitating to get tested.

Conducting the webinar will be Sean McCloy, M.D., a national thought leader who practices internal medicine with an expertise in Lyme disease at the Integrative Health Center of Maine in Portland, Maine. Dr. McCloy will discuss Lyme diagnostic and treatment guidelines and testing options and will outline a newer, faster way to help physicians diagnose and treat Lyme disease. Getting rapid results is not only important to those who test positive but given that the vast majority of patients’ tests are negative, getting results quickly means discernable peace of mind for consumers and removes a significant weight off their shoulders. Not having to wait days or more for test results also allows physicians and nurse practitioners to rapidly treat patients by quickly pursuing other testing if deemed necessary for diagnosis and treatment of Lyme disease.

Among those expected to attend the webinar are representatives of physician office laboratories, urgent care centers and pediatric practices plus any other physicians, allied health professionals and healthcare researchers interested in the subject. The May 13 webinar will take place from 9-10 a.m. (PT). To register, click quidel.com/webinars.

About Quidel Corporation

Quidel Corporation serves to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system. Quidel’s products aid in the detection and diagnosis of many critical diseases and conditions including not only Lyme disease but, among others, influenza, respiratory syncytial virus, strep A, herpes, pregnancy, thyroid disease and fecal occult blood. Quidel’s research and development engine is also developing a continuum of diagnostic solutions from advanced immunoassay to molecular diagnostic tests to further improve the quality of healthcare in physicians’ offices and hospital and reference laboratories. For more information about Quidel, visit quidel.com.

Contacts

Jim Yeager
424-644-0225 (office)
818-264-6812 (mobile)
jim@breakwhitelight.com

Quidel Corporation


Release Summary
Quidel Corporation is hosting a free educational webinar on May 13 to discuss options and clinical applications when testing for Lyme disease.
Release Versions

Contacts

Jim Yeager
424-644-0225 (office)
818-264-6812 (mobile)
jim@breakwhitelight.com

More News From Quidel Corporation

Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation

SAN DIEGO--(BUSINESS WIRE)--Lyme disease is the fastest-growing vector-borne disease in the United States, and its increased prevalence is challenging the scientific community to look for new ways to diagnose and treat this worrisome infection. One answer is found in the discovery of novel drugs; and the breakthrough efforts taking place in this arena are the subject of a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for success...

Bacterial Biofilms, Responsible for Up to 75% of All Infectious Diseases in America, Explored in New Webinar From Quidel Corporation

SAN DIEGO--(BUSINESS WIRE)--The National Institutes of Health reports that bacterial biofilms are responsible for up to 75% of all infectious diseases in humans, including infections of wounds, the lungs and the urinary tract. This important medical reality is now being addressed in a new webinar made available by Quidel Corporation, the California-based diagnostic health care manufacturer known for successfully developing rapid diagnostic health solutions. The webinar, available at https://edu...

Quidel Corp.—Developer of Only FDA-Cleared FIA Rapid Point-of-Care Diagnostic Lyme Disease Test—To Partner With Renowned Global Lyme Alliance to Dramatically Heighten Lyme Disease Awareness

SAN DIEGO--(BUSINESS WIRE)--With Lyme disease season in full-swing across the United States and as the public continues spending increasing time outdoors during the COVID-19 pandemic, Quidel’s recently formed Lyme Task Force Team—the only one of its kind—today announced a multitiered collaboration with Global Lyme Alliance to dramatically heighten public awareness to a health condition afflicting nearly half a million Americans each year. Quidel is the nation’s leading developer of the only rap...
Back to Newsroom